Cargando…

Impact of age on optimal dose of antidepressants

Detalles Bibliográficos
Autor principal:	Hashimoto, Kenji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6948222/ https://www.ncbi.nlm.nih.gov/pubmed/31922121 http://dx.doi.org/10.1016/j.eclinm.2019.12.003

Ejemplares similares

Response Expectancy and the Response to Antidepressant Medication
por: Kirsch, Irving
Publicado: (2017)

Antidepressant drug use and future diabetes risk
por: Kivimäki, M., et al.
Publicado: (2011)

Is Metabolism of (R)-Ketamine Essential for the Antidepressant Effects?
por: Chaki, Shigeyuki
Publicado: (2017)

Is (S)-norketamine an alternative antidepressant for esketamine?
por: Hashimoto, Kenji, et al.
Publicado: (2018)

Optimal doses of antidepressants in dependence on age: Combined covariate actions in Bayesian network meta-analysis
por: Holper, L.
Publicado: (2020)

The media and intellectuals' response to medical publications: the antidepressants' case
por: Fountoulakis, Konstantinos N, et al.
Publicado: (2013)

Current Problems in the Research and Development of more Effective Antidepressants
Publicado: (2016)

Initiating Antidepressant Medication: What is the Most Important Factor?
por: Kasper, Siegfried
Publicado: (2022)

Correlation of antidepressant target dose optimization and achievement of glycemic control
por: Grisham-Takac, Catlin, et al.
Publicado: (2019)

Inflammatory Biomarkers as Differential Predictors of Antidepressant Response
por: Hashimoto, Kenji
Publicado: (2015)

Does the Opioid System Block or Enhance the Antidepressant Effects of Ketamine?
por: Mathew, Sanjay J., et al.
Publicado: (2019)

Embarking on antidepressant response prediction using brain perfusion estimation
por: Sambataro, Fabio, et al.
Publicado: (2019)

Depression, suicidality and antidepressants: A coincidence?
por: Selvaraj, Vithyalakshmi, et al.
Publicado: (2010)

High-quality antidepressant prescribing: please consider whether “perfection is the enemy of progress”
por: Walkup, John T., et al.
Publicado: (2020)

Is the History Repeated? Can (2R,6R)-Hydroxynorketamine be Another Antidepressant?
por: Chaki, Shigeyuki, et al.
Publicado: (2018)

We need to optimize piperacillin-tazobactam dosing in critically ill patients—but how?
por: Cotta, Menino Osbert, et al.
Publicado: (2016)

Dose-Dependent Antidepressant-Like Effects of Cannabidiol in Aged Rats
por: Hernández-Hernández, Elena, et al.
Publicado: (2022)

Announcing the novel class of GABA–A receptor selective positive allosteric modulator antidepressants
por: Fasipe, Olumuyiwa John, et al.
Publicado: (2020)

Enhancing central noradrenergic function in depression: is there still a place for a new antidepressant?
por: Pinder, Roger M
Publicado: (2005)

The Nordic health registers – an important source when evaluating the safety of antidepressants during pregnancy
por: Kieler, Helle
Publicado: (2010)

Activation of σ1-Receptors by R-Ketamine May Enhance the Antidepressant Effect of S-Ketamine
por: Kalkman, Hans O.
Publicado: (2023)

FDA initiatives to support dose optimization in oncology drug development: the less may be the better
por: Moon, Hanlim
Publicado: (2022)

Automated chemotherapy compounding: Process optimization for the preparation of admixture containing high-dose of cyclophosphamide
por: Perego, Gianluca, et al.
Publicado: (2022)

A Medial Prefrontal Cortex Cell Type Necessary and Sufficient for a Rapid Antidepressant Response
por: Hare, Brendan D., et al.
Publicado: (2019)

Optimal radiation dose in the neoadjuvant management of esophageal cancer
por: Buckstein, Michael
Publicado: (2020)

The desperate need for good-quality clinical trials to evaluate the optimal source and dose of fibrinogen in managing bleeding
por: Stanworth, Simon J, et al.
Publicado: (2011)

Comments on the optimal use of medical ozone in clinics versus the Ozone High Dose Therapy (OHT) approach
por: Franzini, Marianno, et al.
Publicado: (2022)

A BDNF Val66Met Polymorphism and Ketamine-induced Rapid Antidepressant Action
por: Hashimoto, Kenji
Publicado: (2012)

Targeting healthspan to optimally combat non-communicable disease in an aging world
por: Drake, Joshua C., et al.
Publicado: (2019)

Beta-lactam antibiotic dosing during continuous renal replacement therapy: how can we optimize therapy?
por: De Waele, Jan J, et al.
Publicado: (2014)

Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor
por: Wei, Yan, et al.
Publicado: (2021)

Do Triptan Antimigraine Medications Interact with SSRI/SNRI Antidepressants? What Does Your Decision Support System Say?
por: Kogut, Stephen J.
Publicado: (2011)

Rapid‐acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective
por: Hashimoto, Kenji
Publicado: (2019)

To dose or not to dose: that is the (starch) question ...
por: Kaplan, Lewis J
Publicado: (2010)

Provide optimized antidepressant monotherapy with multiple drugs before considering antidepressant polypharmacy
por: SAAH, Tammy, et al.
Publicado: (2014)

Optimization of Antidepressant use with Pharmacogenetic Strategies
por: Torrellas, Clara, et al.
Publicado: (2017)

Regulation of the mitochondrial transition pore: impact on mammalian aging
por: Osiewacz, Heinz D.
Publicado: (2011)

A Model-Based Illustrative Exploratory Approach to Optimize the Dosing of Peg-IFN/RBV in Cirrhotic Hepatitis C Patients Treated With Triple Therapy
por: Laouénan, C, et al.
Publicado: (2015)

Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites
por: Yang, Chun, et al.
Publicado: (2019)

Strengthening Routine Health Information Systems to Target Malaria Control Implementation and Optimize Evaluation of Impact
por: Filler, Scott
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_4v0pv2646ahv84dn3ml9996llm